Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease

The significance of sclerostin for bone and cardiovascular health in patients with chronic kidney disease (CKD) is complex and incompletely understood. Experimental evidence suggests that anti-sclerostin therapy shows diminished efficacy on bone in the setting of CKD. Limited clinical evidence sugge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Daniel Cejka
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	sclerostin romosozumab chronic kidney disease (CKD) chronic kidney disease–mineral and bone disorder (CKD–MBD) cardiovascular safety Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/9bdc449e9205454ab300977f5151fe08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9bdc449e9205454ab300977f5151fe08
record_format	dspace
spelling	oai:doaj.org-article:9bdc449e9205454ab300977f5151fe082021-11-25T18:20:48ZCardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease10.3390/metabo111107702218-1989https://doaj.org/article/9bdc449e9205454ab300977f5151fe082021-11-01T00:00:00Zhttps://www.mdpi.com/2218-1989/11/11/770https://doaj.org/toc/2218-1989The significance of sclerostin for bone and cardiovascular health in patients with chronic kidney disease (CKD) is complex and incompletely understood. Experimental evidence suggests that anti-sclerostin therapy shows diminished efficacy on bone in the setting of CKD. Limited clinical evidence suggests that the osteoanabolic and anti-resorptive activity is attenuated, but hypocalcemia is more prevalent in patients with advanced CKD (eGFR < 30 mL/min) treated with anti-sclerostin (romosozumab) therapy as compared to patients without kidney disease. Furthermore, sclerostin is prominently expressed in uremic arteries. Whether the inhibition of sclerostin has adverse effects on cardiovascular health in CKD is currently unknown. This review summarizes the current understanding of the physiology and pathophysiology of sclerostin in CKD, with a focus on the cardiovascular safety of anti-sclerostin therapy in patients with or without CKD.Daniel CejkaMDPI AGarticlesclerostinromosozumabchronic kidney disease (CKD)chronic kidney disease–mineral and bone disorder (CKD–MBD)cardiovascular safetyMicrobiologyQR1-502ENMetabolites, Vol 11, Iss 770, p 770 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sclerostin romosozumab chronic kidney disease (CKD) chronic kidney disease–mineral and bone disorder (CKD–MBD) cardiovascular safety Microbiology QR1-502
spellingShingle	sclerostin romosozumab chronic kidney disease (CKD) chronic kidney disease–mineral and bone disorder (CKD–MBD) cardiovascular safety Microbiology QR1-502 Daniel Cejka Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
description	The significance of sclerostin for bone and cardiovascular health in patients with chronic kidney disease (CKD) is complex and incompletely understood. Experimental evidence suggests that anti-sclerostin therapy shows diminished efficacy on bone in the setting of CKD. Limited clinical evidence suggests that the osteoanabolic and anti-resorptive activity is attenuated, but hypocalcemia is more prevalent in patients with advanced CKD (eGFR < 30 mL/min) treated with anti-sclerostin (romosozumab) therapy as compared to patients without kidney disease. Furthermore, sclerostin is prominently expressed in uremic arteries. Whether the inhibition of sclerostin has adverse effects on cardiovascular health in CKD is currently unknown. This review summarizes the current understanding of the physiology and pathophysiology of sclerostin in CKD, with a focus on the cardiovascular safety of anti-sclerostin therapy in patients with or without CKD.
format	article
author	Daniel Cejka
author_facet	Daniel Cejka
author_sort	Daniel Cejka
title	Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
title_short	Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
title_full	Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
title_fullStr	Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
title_full_unstemmed	Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
title_sort	cardiovascular safety of anti-sclerostin therapy in chronic kidney disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/9bdc449e9205454ab300977f5151fe08
work_keys_str_mv	AT danielcejka cardiovascularsafetyofantisclerostintherapyinchronickidneydisease
_version_	1718411334424461312

Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease

Ejemplares similares